Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10145)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PPARG
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Intracerebral hemorrhage | ICD-11: 8B00 | |||
Responsed Drug | Pioglitazone | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNCs (Rat primary nerve cells) | ||||
hBCs (Brain cells) | |||||
In Vivo Model |
The rats underwent surgery using an ultraclean table and were fixed in a stereotaxic frame. The scalp was opened to expose the anterior brain region. A dental drill was used to drill a 1-mm-diameter hole in the skull surface. Blood (100 ul) was collected from the rat tail vein and injected into the rat striatum with a microsyringe (stereotaxic coordinates; 2 mm lateral to the midline, 0.2 mm posterior to bregma, and 5.5 mm deep below the skull). First, 60 ul of autogenous blood were injected at a rate of 2 ul/min, and the next 40 ul of blood were injected at 5 ul/min. Finally, the needle was left for 10 min before being removed.
Click to Show/Hide
|
||||
Response regulation | Pioglitazone (PDZ), a PPAR agonist, promotes Gpx4 expression through the interaction between PPAR and the Nrf2 pathway, inhibits ferroptosis of neurons after intracerebral hemorrhage (ICH), and promotes the recovery of neural function. | ||||
Nuclear factor erythroid 2-related factor 2 (NFE2L2) [Suppressor; Marker]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Intracerebral hemorrhage | ICD-11: 8B00 | |||
Responsed Drug | Pioglitazone | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNCs (Rat primary nerve cells) | ||||
hBCs (Brain cells) | |||||
In Vivo Model |
The rats underwent surgery using an ultraclean table and were fixed in a stereotaxic frame. The scalp was opened to expose the anterior brain region. A dental drill was used to drill a 1-mm-diameter hole in the skull surface. Blood (100 ul) was collected from the rat tail vein and injected into the rat striatum with a microsyringe (stereotaxic coordinates; 2 mm lateral to the midline, 0.2 mm posterior to bregma, and 5.5 mm deep below the skull). First, 60 ul of autogenous blood were injected at a rate of 2 ul/min, and the next 40 ul of blood were injected at 5 ul/min. Finally, the needle was left for 10 min before being removed.
Click to Show/Hide
|
||||
Response regulation | Pioglitazone (PDZ), a PPAR agonist, promotes Gpx4 expression through the interaction between PPAR and the Nrf2 pathway, inhibits ferroptosis of neurons after intracerebral hemorrhage (ICH), and promotes the recovery of neural function. | ||||
Unspecific Target [Unspecific Target]
In total 2 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | |||
Responsed Disease | Diabetes mellitus | ICD-11: 5A10 | ||
Responsed Drug | Resveratrol | Phase 3 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
MIN6 cells | Insulinoma | Mus musculus | CVCL_0431 |
Response regulation | Acrolein is a typical food and environmental pollutant and a risk factor for diabetes. Resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPAR expression, thereby inhibiting acrolein-induced ferroptosis. | |||
Experiment 2 Reporting the Ferroptosis Target of This Regulator | [2] | |||
Responsed Disease | Diabetes mellitus | ICD-11: 5A10 | ||
Responsed Drug | Acrolein | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
MIN6 cells | Insulinoma | Mus musculus | CVCL_0431 |
Response regulation | Acrolein is a typical food and environmental pollutant and a risk factor for diabetes. Resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPAR expression, thereby inhibiting acrolein-induced ferroptosis. | |||
Intracerebral hemorrhage [ICD-11: 8B00]
In total 2 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Peroxisome proliferator-activated receptor gamma (PPARG) | Protein coding | |||
Responsed Drug | Pioglitazone | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNCs (Rat primary nerve cells) | ||||
hBCs (Brain cells) | |||||
In Vivo Model |
The rats underwent surgery using an ultraclean table and were fixed in a stereotaxic frame. The scalp was opened to expose the anterior brain region. A dental drill was used to drill a 1-mm-diameter hole in the skull surface. Blood (100 ul) was collected from the rat tail vein and injected into the rat striatum with a microsyringe (stereotaxic coordinates; 2 mm lateral to the midline, 0.2 mm posterior to bregma, and 5.5 mm deep below the skull). First, 60 ul of autogenous blood were injected at a rate of 2 ul/min, and the next 40 ul of blood were injected at 5 ul/min. Finally, the needle was left for 10 min before being removed.
Click to Show/Hide
|
||||
Response regulation | Pioglitazone (PDZ), a PPAR agonist, promotes Gpx4 expression through the interaction between PPAR and the Nrf2 pathway, inhibits ferroptosis of neurons after intracerebral hemorrhage (ICH), and promotes the recovery of neural function. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Peroxisome proliferator-activated receptor gamma (PPARG) | Protein coding | |||
Responsed Drug | Pioglitazone | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNCs (Rat primary nerve cells) | ||||
hBCs (Brain cells) | |||||
In Vivo Model |
The rats underwent surgery using an ultraclean table and were fixed in a stereotaxic frame. The scalp was opened to expose the anterior brain region. A dental drill was used to drill a 1-mm-diameter hole in the skull surface. Blood (100 ul) was collected from the rat tail vein and injected into the rat striatum with a microsyringe (stereotaxic coordinates; 2 mm lateral to the midline, 0.2 mm posterior to bregma, and 5.5 mm deep below the skull). First, 60 ul of autogenous blood were injected at a rate of 2 ul/min, and the next 40 ul of blood were injected at 5 ul/min. Finally, the needle was left for 10 min before being removed.
Click to Show/Hide
|
||||
Response regulation | Pioglitazone (PDZ), a PPAR agonist, promotes Gpx4 expression through the interaction between PPAR and the Nrf2 pathway, inhibits ferroptosis of neurons after intracerebral hemorrhage (ICH), and promotes the recovery of neural function. | ||||
Diabetes mellitus [ICD-11: 5A10]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | |||
Target Regulator | Peroxisome proliferator-activated receptor gamma (PPARG) | Protein coding | ||
Responsed Drug | Resveratrol | Phase 3 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
MIN6 cells | Insulinoma | Mus musculus | CVCL_0431 |
Response regulation | Acrolein is a typical food and environmental pollutant and a risk factor for diabetes. Resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPAR expression, thereby inhibiting acrolein-induced ferroptosis. | |||
Experiment 2 Reporting the Ferroptosis-centered Disease Response | [2] | |||
Target Regulator | Peroxisome proliferator-activated receptor gamma (PPARG) | Protein coding | ||
Responsed Drug | Acrolein | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
MIN6 cells | Insulinoma | Mus musculus | CVCL_0431 |
Response regulation | Acrolein is a typical food and environmental pollutant and a risk factor for diabetes. Resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPAR expression, thereby inhibiting acrolein-induced ferroptosis. | |||
Pioglitazone
[Investigative]
In total 2 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Suppressor | ||||
Response Target | Phospholipid hydroperoxide glutathione peroxidase (GPX4) | Suppressor | |||
Responsed Disease | Intracerebral hemorrhage | ICD-11: 8B00 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNCs (Rat primary nerve cells) | ||||
hBCs (Brain cells) | |||||
In Vivo Model |
The rats underwent surgery using an ultraclean table and were fixed in a stereotaxic frame. The scalp was opened to expose the anterior brain region. A dental drill was used to drill a 1-mm-diameter hole in the skull surface. Blood (100 ul) was collected from the rat tail vein and injected into the rat striatum with a microsyringe (stereotaxic coordinates; 2 mm lateral to the midline, 0.2 mm posterior to bregma, and 5.5 mm deep below the skull). First, 60 ul of autogenous blood were injected at a rate of 2 ul/min, and the next 40 ul of blood were injected at 5 ul/min. Finally, the needle was left for 10 min before being removed.
Click to Show/Hide
|
||||
Response regulation | Pioglitazone (PDZ), a PPAR agonist, promotes Gpx4 expression through the interaction between PPAR and the Nrf2 pathway, inhibits ferroptosis of neurons after intracerebral hemorrhage (ICH), and promotes the recovery of neural function. | ||||
Experiment 2 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Suppressor | ||||
Response Target | Nuclear factor erythroid 2-related factor 2 (NFE2L2) | Suppressor; Marker | |||
Responsed Disease | Intracerebral hemorrhage | ICD-11: 8B00 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNCs (Rat primary nerve cells) | ||||
hBCs (Brain cells) | |||||
In Vivo Model |
The rats underwent surgery using an ultraclean table and were fixed in a stereotaxic frame. The scalp was opened to expose the anterior brain region. A dental drill was used to drill a 1-mm-diameter hole in the skull surface. Blood (100 ul) was collected from the rat tail vein and injected into the rat striatum with a microsyringe (stereotaxic coordinates; 2 mm lateral to the midline, 0.2 mm posterior to bregma, and 5.5 mm deep below the skull). First, 60 ul of autogenous blood were injected at a rate of 2 ul/min, and the next 40 ul of blood were injected at 5 ul/min. Finally, the needle was left for 10 min before being removed.
Click to Show/Hide
|
||||
Response regulation | Pioglitazone (PDZ), a PPAR agonist, promotes Gpx4 expression through the interaction between PPAR and the Nrf2 pathway, inhibits ferroptosis of neurons after intracerebral hemorrhage (ICH), and promotes the recovery of neural function. | ||||
Resveratrol
[Phase 3]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [2] | |||
Drug for Ferroptosis | Suppressor | |||
Response Target | Unspecific Target | |||
Responsed Disease | Diabetes mellitus | ICD-11: 5A10 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
MIN6 cells | Insulinoma | Mus musculus | CVCL_0431 |
Response regulation | Acrolein is a typical food and environmental pollutant and a risk factor for diabetes. Resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPAR expression, thereby inhibiting acrolein-induced ferroptosis. | |||
Acrolein
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [2] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Unspecific Target | |||
Responsed Disease | Diabetes mellitus | ICD-11: 5A10 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
MIN6 cells | Insulinoma | Mus musculus | CVCL_0431 |
Response regulation | Acrolein is a typical food and environmental pollutant and a risk factor for diabetes. Resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPAR expression, thereby inhibiting acrolein-induced ferroptosis. | |||
References